EFFECT OF KELTICAN AND POLARIZING LIGHT ON LIPID PEROXIDATION AND ANTIOXIDANT DEFENSES IN TYPE 2 DIABETES MELLITUS WITH DIABETIC POLYNEUROPATHY AND DYSLIPIDEMIA
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i3.9284Keywords:
diabetic polyneuropathy, oxidative stress, lipid metabolism, keltican, polarizing lightAbstract
Patients with type 2 diabetes mellitus (DM) suffer from dysfunction of lipid peroxidation processes, resulting in abnormal functioning of cell membrane structures, which leads to their increased destruction, and may be a factor in the progression of diabetic polyneuropathy (DPN) complication.
The aim of the study was to learn the effects of complex treatment with incorportion of the Keltican drug and polarizing light on LPO and AOP indicators in patients with type 2 diabetes with diabetic polyneuropathy and dyslipidemia.
Material and Methods. 130 patients with type 2 diabetes, complicated by diabetic polyneuropathy were examined. Patients were divided into 4 groups: 32 patients in group 1 received standard treatment, 32 patients in group 2 additionally received 1 capsule of Keltican three times a day for one month. For 35 diabetics of group 3, 12 therapeutic procedures were additionally assigned with polarizing light. 31 patients in the group 4, in addition to standard treatment, received Keltican combined with polarizing light therapy course.
The state of LPO was assessed by the content of conjugated dienes and malondialdehyde (MDA). The antioxidant protection (AOP) activity was studied by concentration of superoxide dismutase (SOD), catalase and glutathione reductase (SH-group).
Cholesterol levels, as well as fractions of HDL (high density lipoprotein), LDL (low density lipoprotein) and TG (triglycerides) were determined to assess lipid metabolism.
Results. Inclusion of Keltican and polarizing light in the standard treatment of DPN has a more pronounced effect on LPO and AOP compared to standard treatment. The results of lipidograms are most closely related to the target level under the influence of treatment in the group 4.
Conclusion. Inclusion of the drug Keltican and light therapeutic procedures in the standard therapy of DPN in patients with type 2 diabetes and dyslipidemia had an adjusting impact on LPO and AOP indicators.
References
Giacco, F., M. Brownlee. (2010) Oxidative stress and diabetic complications. Cir. Res., 107, 1058-1070.
Evans, J.L., Goldfine, I.D., Maddux, B.A., & Grodsky, G.M. (2002). Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrine Rev., 23, 5, 599-622.
Vincent, A.M., Russel, J.W., Low, P., & Feldman, E.L. (2004). Oxidative stress in the pathogenesis of diabetic neuropathy. Endocrinol., 25, 4, 612-628.
Popova, T.N., Aharkov, A.A., & Verevkin, A.N. (2013). Intensivnost svobodnoradikalnykh protsessov v pecheni krys pri sakharnom diabete 2 tipa i vvedenii epifamina [Intensity of free radical processes in liver of rats with type 2 diabetes mellitus and administration of epifamine]. Еksperementalni statti – Experimental Articles, 4 (19), 129-134 [in Russian].
Ishonina, O.G., Mikashinovich, Z.I., Olempieva, E.V., & Kovalenko, T.D. (2011). Comparative characteristics of antioxidant status in women with diabetes type 2 of different age groups. Adv. Gerontol, 24 (4), 645-649.
Bardymova, T.P., Kolesnikova, L.I., & Petrova, V.A. (2005). Perekisnoe okisleniye lipidov, antioksidantnaya sistema u bolnykh sakharnym diabetom II tipa [Peroxide oxidation of lipids, antioxidant system in patients with type II diabetes mellitus]. Byulleten VSNTs SO RAMN – Journal of VSNTs SO RAMN, 6 (44), 50-54 [in Russian].
Sorokina, Yu.A., & Lovtsova, L.V. (2015). Koefitsiyent okislitelnogo stressa kak sposob personifitsirovaniya farmakoterapii v debyute SD 2 tipa [Oxidizing stress factors as a method of personification of pharmacotherapy in the type 2]. Universum: Meditsina i farmakologiya: El. nauchn. Zhurn. – Universum: Medicine and Pharmacology: Electronic Scientific Journal, 1 (14). Retrieved from: http://7universum.com/ ru/med/archive/item/1868 [in Russian].
Balabolkin, M.I., Klebanova, E.M., & Kreminskaya, V.M. (2005). Lecheniye sakharnogo diabeta i ego oslozhneniy [Treatment of diabetes mellitus and its complications]. Moscow: Meditsina [in Russian].
Balabolkin, M.I. (2002). Rol glikirovaniya belkov, okislitelnogo stressa v patogeneze sosudistykh oslozhneniy pri sakharnom diabete [The role of glycation of proteins, oxidative stress in the pathogenesis of vascular complications in diabetes mellitus]. Sakharnyy diabet – Diabetes Mellitus, 4, 5-16 [in Russian].
Zanozina, O.V., Sorokina, A.N., Borovkov, N.N., & Shcherbatyuk, T.G. (2013). “Porochyy krug” vzamosvyazi perekisnogo okisleniya lipidov i okislitelnoy modifikatsii belkov u bolnykh sakharnym diabetom 2 tipa ["Defective circle" of interconnections of lipid peroxidation and oxidative modification of proteins in patients with type 2 diabetes mellitus]. Meditsinskiy almanakh – Medical Almanac, 6, 167-170 [in Russian].
Zanozina, O.V. (2010). Rol okislytelnogo stressa v razvitii i progressirovanii pozdnikh oslozhneniy sakharnogo diabeta 2 tipa. Vozmozhnosti antioksydantnoy terapii [The role of oxidative stress in the development and progression of late complications of type 2 diabetes. Possibilities of antioxidant therapy]. Doctor’s Extended abstract. N. Novgorod [in Russian].
Zanozina, O.V. (2010). Rol okislitelnogo stressa v razvitii i progressirovanii pozdnikh oslozhneniy sakharnogo diabeta 2-go tipa. Vozmozhnosti antioksydantnoy terapii [The role of oxidative stress in the development and progression of late complications of type 2 diabetes mellitus. Antioxidant therapy possibilities]. Mizhnarodnyi endokrynolohichnyi zhurnal – International Endocrinological Journal, 7 (31) [in Russian].
Sharma, R.B., & Alonso, L.C. (2014). Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well? Curr. Diab. Rep., 14 (6), 492. doi: 10.1007/ s11892-014-0492-2.
Horyushkina, O.A., & Vasilyeva, E.M. (2013). Antioksidantnaya terapiya v korrektsii oksidativnogo stressa u bolnykh ishemicheskoy boleznyu serdtsa s sakharnym diabetom 2-go tipa [Antioxidant therapy in the correction of oxidative stress in patients with ischemic heart disease with type 2 diabetes mellitus]. Vestnik novykh meditsynskikh tekhnologiy – Journal of New Medical Technologies, ХX (2),156 [in Russian].
Morgantini, C., Meriwether, D., & Baldi, S. (2014). HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr. Metab. Cardiovasc. Dis. 24 (6), 594-599. doi: 10.1016/j. numecd.2013.12.011.
Martynyuk, L.P., Shved, M.I. Makarchuk, N.R., & Chernetskyi, V.I. (2018). The ways of improvement of the life quality of the patients with diabetic neuropathy. European Scientific Journal, 1 (29), 39-41.
Shved, M.I., Makarchuk, N.R., & Martyniuk, L.P. (2017). Klinichna efektyvnist vykorystannia kombinovanoho aminokyslotnoho kompleksu v likuvanni khvorykh na diabetychnu polineiropatiiu [Clinical efficiency of using the combined amino acid complex in the treatment of patients with diabetic polyneuropathy]. Zhurnal Visnyk naukovykh doslidzhen – Journal of Scientific Researches, 3, 60-63 [in Ukrainian].
Nakaz MOZ Ukrainy vid 21.12.2012 №1118 “Pro zatverdzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsiieiu medychnoi dopomohy pry tsukrovomu diabeti 2 typu” [Order of the Ministry of Health of Ukraine dated December 21, 2012 No. 1118 "On Approval of Medical-Technological Documents with Standardization of Medical Assistance in Type 2 Diabetes" Order of the Ministry of Health of Ukraine]. Retrieved from: //www/moz.qov.ua/ua/portal/dn_20121221_1118.html [in Ukrainian].
